De Santis M, Straface G, Cavaliere A F, Rosati P, Batocchi A P, Caruso A
Telefono Rosso, Teratogen Information Service, Institute of Obstetrics and Gynecology, Catholic University of the Sacred Heart, Rome, Italy.
Neurotoxicology. 2007 May;28(3):696-7. doi: 10.1016/j.neuro.2006.10.002. Epub 2006 Oct 20.
Mitoxantrone is an antineoplastic agent considered a potential human teratogen because of its mechanism of action and is classified by the US Food and Drug Administration in pregnancy category risk D. In the literature there are only four cases of women exposed to the drug in late pregnancy. We report the first case of mitoxantrone therapy in the first trimester and during the pregnancy. A 41-year-old woman affected with multiple sclerosis, conceived during therapy and continued mitoxantrone until 29 weeks and 3 days of her pregnancy. She delivered by cesarean section at 39 weeks a growth restricted female baby weighing 1950g without evidence of congenital malformations.
米托蒽醌是一种抗肿瘤药物，因其作用机制被认为是一种潜在的人类致畸剂，美国食品药品监督管理局将其归类为妊娠风险D类药物。文献中仅有4例妊娠晚期接触该药物的女性病例。我们报告首例在孕早期及整个孕期使用米托蒽醌治疗的病例。一名41岁的患有多发性硬化症的女性在治疗期间怀孕，并继续使用米托蒽醌直至怀孕29周零3天。她在39周时剖宫产分娩出一名体重1950g的生长受限女婴，未发现先天性畸形。
